459 related articles for article (PubMed ID: 26825065)
1. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
2. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
[TBL] [Abstract][Full Text] [Related]
3. Response to treatment with intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligo articular juvenile idiopathic arthritis.
Harhay R; Jeelani W; Agbor BTA; Hennon T; Wrotniak BH; Abdul-Aziz R
Pediatr Rheumatol Online J; 2021 Mar; 19(1):36. PubMed ID: 33743721
[TBL] [Abstract][Full Text] [Related]
4. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
5. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid treatment in juvenile idiopathic arthritis.
Batu ED
Rheumatol Int; 2019 Jan; 39(1):13-27. PubMed ID: 30276425
[TBL] [Abstract][Full Text] [Related]
7. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
8. Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: Analysis of United States Commercial Insurance Data.
Horton DB; Yang Y; Neikirk A; Huang C; Crystal S; Davidow A; Haynes K; Gerhard T; Rose CD; Strom BL; Parlett L
J Clin Rheumatol; 2023 Dec; 29(8):388-395. PubMed ID: 37798830
[TBL] [Abstract][Full Text] [Related]
9. Biologics in juvenile idiopathic arthritis: a narrative review.
Vanoni F; Minoia F; Malattia C
Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
[TBL] [Abstract][Full Text] [Related]
10. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
[TBL] [Abstract][Full Text] [Related]
11. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
Brik R; Gepstein V; Berkovitz D
Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
13. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids.
Vivarelli M; D'Urbano LE; Insalaco A; Lunt M; Jury F; Tozzi AE; Ravelli A; Martini A; Donn R; De Benedetti F
Clin Exp Rheumatol; 2007; 25(5):775-81. PubMed ID: 18078632
[TBL] [Abstract][Full Text] [Related]
16. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
[TBL] [Abstract][Full Text] [Related]
17. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.
Tiller G; Buckle J; Allen R; Munro J; Gowdie P; Cox A; Akikusa J
Pediatr Rheumatol Online J; 2018 Nov; 16(1):69. PubMed ID: 30413164
[TBL] [Abstract][Full Text] [Related]
18. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
[TBL] [Abstract][Full Text] [Related]
19. Juvenile idiopathic arthritis--current and future therapies.
Kahn P
Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
